BioVacSafe Project BioVacSafe Project

Welcome to BioVacSafe Project

BioVacSafe - Biomarkers for enhanced vaccines immunosafety - is a 5 years project funded by Innovative Medicine initiative (IMI).

The goal of BioVacSafe is to develop cutting edge tools to speed up and improve the testing and monitoring of vaccine safety, both before and after release to the market. By  bringing  together for the first time three of Europe's  leading  vaccine  development  and manufacture companies as well as top experts from academic institutions and small and medium-sized enterprises (SMEs),  the project will ultimately accelerate the development and introduction of a new generation of safer, more effective vaccines. By sharing their expertise, the BioVacSafe partners have a unique opportunity to make progress in this important area.

Project Description

On March 1st 2012 the IMI-JU funded project – Biomarkers for Enhanced Vaccine Safety (BioVacSafe) – initiated its collaborative work to develop new tools that will improve the evaluation and monitoring of vaccine immunosafety.

BioVacSafe is a public private consortium of 19 partners involving three of Europe's leading vaccine producing companies, experts from major academic institutions, small and medium-sized enterprises (SMEs) and non-governmental organization (NGO) actors.

The total budget of the project is 30.2 millions of Euros and it will last for five years.

Read more

Follow us:

facebook twitter linkedin

Project Objectives

The overall objective of the project is to develop cutting edge tools to speed up and improve the testing and monitoring of vaccine safety, both before and after release to the market.

The three specific objectives of the project are:

• the characterization of early inflammation induced by vaccines currently on the market and the identification and validation of biomarkers of early inflammation and allergic responses;

• the identification and validation of early biomarkers of autoimmunity and their use to help identifying population at risk of developing autoimmunity;

• the analysis of the incidence and epidemiology of autoimmune disease in the general population and the link to genetic background or previous events in the life of patients, including severe effects, such as anaphylactic shock.

 

BioVacSafe Meetings BioVacSafe Meetings

BioVacSafe 4th Annual Meeting 2016

took place in Lyon from the 9th to the 11th of March 2016 at Novotel Lyon Gerland. 

Here you can find the Proceedings of the General Annual Meeting.


New Publications New Publications

New Publication acknowledging BioVacSafe

New Publication acknowledging BioVacSafe Early Rise of Blood T Follicular Helper Cell Subsets and Baseline Immunity as Predictors of Persisting Late Functional Antibody Responses to...

Events Events

Mucosal Vaccines, Adjuvants & Delivery

Mucosal Vaccines, Adjuvants & Delivery 14-16th September 2016 Mucosal Vaccines,...

46th Annual Meeting of the German Society for Immunology

46th Annual Meeting of the German Society for Immunology 27-30th September 2016 46th...

10th Vaccine Congress

10th Vaccine Congress 4-7th September 2016 10 th Vaccine Congress   will...

10th ISV Annual Vaccine Congress

10th ISV Annual Vaccine Congress 2nd -4th October 2016 10th ISV Annual Vaccine...